Andere Sprachen NextCure, Inc.

Aktien

A2PHHE

US65343E1082

NXTC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
1.35 ^USD	+4.65%		-15.62%	+18.42%

08.04.	NextCure, Inc. und LigaChem Biosciences, Inc. präsentieren präklinische Daten zu B7-H4-Antikörper-Wirkstoffkonjugat auf der AACR 2024	CI
04.04.	NextCure, Inc. ernennt Rakesh Dixit zum wissenschaftlichen Beirat	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024	24.04.
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024	08.04.
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	08.04.
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board	04.04.
NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board	04.04.
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference	02.04.
NextCure : March 2024 Corporate Presentation	21.03.
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
NextCure Provides Business Update and Reports Full Year 2023 Financial Results	21.03.
North American Morning Briefing : Markets on Hold -2-	20.03.
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances	05.03.
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances	05.03.
Top Premarket Decliners	27.02.
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	18.01.
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	18.01.
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	21.12.
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	21.12.
Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	21.12.
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20.12.
NextCure Provides Year-End Clinical Pipeline Updates	14.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NextCure, Inc.

Aktien

A2PHHE

US65343E1082

NXTC

Andere Sprachen

Filter